AllianzGI Health Sciences B
Name
As ofPrice
Aum/Mkt Cap
YIELD
Exp Ratio
Watchlist
Vitals
YTD Return
N/A
1 yr return
8.6%
3 Yr Avg Return
22.2%
5 Yr Avg Return
18.5%
Net Assets
$207 M
Holdings in Top 10
31.5%
52 WEEK LOW AND HIGH
Expenses
OPERATING FEES
Expense Ratio 2.21%
SALES FEES
Front Load N/A
Deferred Load 5.00%
TRADING FEES
Turnover 76.00%
Redemption Fee N/A
Min Investment
Standard (Taxable)
$1,000
IRA
$1,000
Fund Classification
Fund Type
Open End Mutual Fund
Name
As ofPrice
Aum/Mkt Cap
YIELD
Exp Ratio
Watchlist
RBGHX - Profile
Distributions
- YTD Total Return N/A
- 3 Yr Annualized Total Return 21.5%
- 5 Yr Annualized Total Return 18.3%
- Capital Gain Distribution Frequency Annually
- Net Income Ratio -1.48%
- Dividend Yield 0.0%
- Dividend Distribution Frequency Annually
Fund Details
-
Legal NameAllianzGI Health Sciences Fund
-
Fund Family NameAllianz Funds
-
Inception DateFeb 05, 2002
-
Shares OutstandingN/A
-
Share ClassB
-
CurrencyUSD
-
Domiciled CountryUnited States
-
ManagerJohn R. Schroer
Fund Description
RBGHX - Performance
Return Ranking - Trailing
Period | RBGHX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
YTD | N/A | 2.0% | 37.7% | N/A |
1 Yr | 8.6% | -25.0% | 10.1% | N/A |
3 Yr | 22.2%* | -17.4% | 21.9% | N/A |
5 Yr | 18.5%* | -11.0% | 18.6% | N/A |
10 Yr | 9.8%* | -1.9% | 15.7% | N/A |
* Annualized
Return Ranking - Calendar
Period | RBGHX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
2023 | N/A | -25.3% | 7.7% | N/A |
2022 | N/A | -10.8% | 43.9% | N/A |
2021 | N/A | -29.8% | 2.6% | N/A |
2020 | N/A | -20.4% | 13.8% | N/A |
2019 | N/A | -5.8% | 31.5% | N/A |
Total Return Ranking - Trailing
Period | RBGHX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
YTD | N/A | 2.0% | 37.7% | N/A |
1 Yr | 3.9% | -25.0% | 13.9% | N/A |
3 Yr | 21.5%* | -17.4% | 25.0% | N/A |
5 Yr | 18.3%* | -11.0% | 20.7% | N/A |
10 Yr | 9.8%* | -1.9% | 18.9% | N/A |
* Annualized
Total Return Ranking - Calendar
Period | RBGHX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
2023 | N/A | -25.3% | 12.3% | N/A |
2022 | N/A | -10.8% | 45.8% | N/A |
2021 | N/A | -24.2% | 8.7% | N/A |
2020 | N/A | -16.6% | 15.2% | N/A |
2019 | N/A | -5.8% | 36.7% | N/A |
RBGHX - Holdings
Concentration Analysis
RBGHX | Category Low | Category High | RBGHX % Rank | |
---|---|---|---|---|
Net Assets | 207 M | 13.8 M | 44.7 B | N/A |
Number of Holdings | 78 | 30 | 398 | N/A |
Net Assets in Top 10 | 64.1 M | 6.7 M | 18.8 B | N/A |
Weighting of Top 10 | 31.47% | 25.1% | 75.2% | N/A |
Top 10 Holdings
- UnitedHealth Group Inc 4.21%
- Celgene Corp 3.74%
- AbbVie Inc 3.29%
- Eagle Pharmaceuticals Inc 3.09%
- Alexion Pharmaceuticals Inc 3.08%
- Regeneron Pharmaceuticals Inc 3.02%
- Bristol-Myers Squibb Company 2.96%
- Mylan NV 2.75%
- Vertex Pharmaceuticals Inc 2.70%
- Shire PLC 2.65%
Asset Allocation
Weighting | Return Low | Return High | RBGHX % Rank | |
---|---|---|---|---|
Stocks | 96.10% | 91.85% | 103.82% | N/A |
Cash | 3.90% | 0.00% | 5.40% | N/A |
Preferred Stocks | 0.00% | 0.00% | 2.32% | N/A |
Other | 0.00% | -3.83% | 2.75% | N/A |
Convertible Bonds | 0.00% | 0.00% | 0.12% | N/A |
Bonds | 0.00% | 0.00% | 0.94% | N/A |
Stock Sector Breakdown
Weighting | Return Low | Return High | RBGHX % Rank | |
---|---|---|---|---|
Healthcare | 93.95% | 13.80% | 99.42% | N/A |
Technology | 1.58% | 0.00% | 61.10% | N/A |
Consumer Defense | 0.55% | 0.00% | 0.69% | N/A |
Utilities | 0.00% | 0.00% | 0.00% | N/A |
Real Estate | 0.00% | 0.00% | 1.36% | N/A |
Industrials | 0.00% | 0.00% | 10.61% | N/A |
Financial Services | 0.00% | 0.00% | 5.80% | N/A |
Energy | 0.00% | 0.00% | 0.09% | N/A |
Communication Services | 0.00% | 0.00% | 0.00% | N/A |
Consumer Cyclical | 0.00% | 0.00% | 7.87% | N/A |
Basic Materials | 0.00% | 0.00% | 1.91% | N/A |
Stock Geographic Breakdown
Weighting | Return Low | Return High | RBGHX % Rank | |
---|---|---|---|---|
US | 84.30% | 60.46% | 99.31% | N/A |
Non US | 11.80% | 0.00% | 39.02% | N/A |
RBGHX - Expenses
Operational Fees
RBGHX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Expense Ratio | 2.21% | 0.10% | 2.98% | N/A |
Management Fee | 1.20% | 0.09% | 1.25% | N/A |
12b-1 Fee | 1.00% | 0.00% | 1.00% | N/A |
Administrative Fee | 0.40% | 0.01% | 0.40% | N/A |
Sales Fees
RBGHX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Front Load | N/A | 2.50% | 5.75% | N/A |
Deferred Load | 5.00% | 1.00% | 5.00% | N/A |
Trading Fees
RBGHX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Max Redemption Fee | N/A | 0.75% | 2.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
RBGHX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Turnover | 76.00% | 0.00% | 341.00% | N/A |
RBGHX - Distributions
Dividend Yield Analysis
RBGHX | Category Low | Category High | RBGHX % Rank | |
---|---|---|---|---|
Dividend Yield | 0.00% | 0.00% | 0.01% | N/A |
Dividend Distribution Analysis
RBGHX | Category Low | Category High | Category Mod | |
---|---|---|---|---|
Dividend Distribution Frequency | Annually | Annually | Semi-Annually | Annually |
Net Income Ratio Analysis
RBGHX | Category Low | Category High | RBGHX % Rank | |
---|---|---|---|---|
Net Income Ratio | -1.48% | -2.15% | 1.48% | N/A |
Capital Gain Distribution Analysis
RBGHX | Category Low | Category High | Capital Mode | |
---|---|---|---|---|
Capital Gain Distribution Frequency | Annually | Annually | Semi-Annually | Annually |
RBGHX - Fund Manager Analysis
Managers
John R. Schroer
Start Date
Tenure
Tenure Rank
Jan 13, 2014
1.88
1.9%
Mr. Schroer, CFA, is a portfolio manager and a director with Allianz Global Investors, which he joined in 2014. Mr. Schroer has more than 20 years of investment-industry experience. He was previously the president of Schroer Capital, L.P.; an equity analyst with HealthCor Management, L.P.; a managing member and portfolio manager for ITROS Capital Management, LLC; a global partner, senior vice president, and portfolio manager for INVESCO; and an analyst for Trust Company of the West. Mr. Schroer has a B.S. an M.B.A. in finance from the University of Wisconsin.
Michael Dauchot
Start Date
Tenure
Tenure Rank
Mar 01, 2005
10.76
10.8%
Dr. Dauchot, CFA, is a portfolio manager, a senior research analyst and a director with Allianz Global Investors, which he joined in 1999. He is part of the Health Care team, focusing on medical technology and emerging pharmaceuticals. Dr. Dauchot has 17 years of investment-industry experience. He previously worked at Pequot Capital Management and BancBoston Robertson Stephens. Dr. Dauchot has a degree in chemistry from Case Western Reserve University, an M.B.A. from the Kellogg School of Management at Northwestern University and an M.D. from the University of Cincinnati College of Medicine.
Tenure Analysis
Category Low | Category High | Category Average | Category Mode |
---|---|---|---|
0.08 | 21.8 | 10.26 | 19.18 |